Utilizing a dual endogenous reporter system to identify functional regulators of aberrant stem cell and differentiation activity in colorectal cancer.
Sandor SpisakDavid ChenPornlada LikasitwatanakulPaul DoanZhixin LiPratyusha BalaLaura VizkeletiViktoria TiszaPushpamail De SilvaMarios GiannakisBrian WolpinJun QiNilay S SethiPublished in: bioRxiv : the preprint server for biology (2024)
Aberrant stem cell-like activity and impaired differentiation are central to the development of colorectal cancer (CRC). To identify functional mediators that regulate these key cellular programs in CRC, we developed an endogenous reporter system by genome-editing human CRC cell lines with knock-in fluorescent reporters at the SOX9 and KRT20 locus to report aberrant stem cell-like activity and differentiation, respectively, and then performed pooled genetic perturbation screens. Constructing a dual reporter system that simultaneously monitored aberrant stem cell-like and differentiation activity in the same CRC cell line improved our signal to noise discrimination. Using a focused-library CRISPR screen targeting 78 epigenetic regulators with 542 sgRNAs, we identified factors that contribute to stem cell-like activity and differentiation in CRC. Perturbation single cell RNA sequencing (Perturb-seq) of validated hits nominated SMARCB1 of the BAF complex (also known as SWI/SNF) as a negative regulator of differentiation across an array of neoplastic colon models. SMARCB1 is a dependency in CRC and required for in vivo growth of human CRC models. These studies highlight the utility of a biologically designed endogenous reporter system to uncover novel therapeutic targets for drug development.
Keyphrases
- stem cells
- crispr cas
- genome editing
- single cell
- genome wide
- endothelial cells
- high throughput
- transcription factor
- public health
- rna seq
- dna methylation
- gene expression
- cell therapy
- randomized controlled trial
- induced pluripotent stem cells
- high resolution
- quantum dots
- mass spectrometry
- mesenchymal stem cells
- open label
- single molecule
- cancer therapy
- study protocol
- high density